Sign inJoin waitlistJoin the waitlist

Changchun Deng

Medical Director, Lymphoma and CLL, UH Seidman Cancer Center · Case Western Reserve University/University Hospitals Cleveland Medical Center

Credentials: · · · · · ·

History

Lymphoma and CLL · Case Western Reserve University/University Hospitals Cleveland Medical Center
Present
Clinical Trials Unit · Case Western Reserve University/University Hospitals Cleveland Medical Center
Present
Case Western Reserve University
Present

Hematology and Medical Oncology
New York Presbyterian Hospital
2008–2010
Hematology and Medical Oncology
University of Texas Southwestern Medical Center
2007–2008
Internal Medicine
Lincoln Medical and Mental Health Center
2004–2007
Stanford University
2001–2004
University of Pittsburgh
1994–2001
Suzhou Medical College
1986–1990

Research

Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation,…
The Lancet Oncology · 2018 · 179 citations
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study
Blood · 2021 · 162 citations
Integrating phenotypic and expression profiles to map arsenic-response networks
Genome biology · 2004 · 144 citations

OO
Owen O’Connor
21 papers
AS
Ahmed Sawas
11 papers
Jennifer Amengual
9 papers
JL
Jennifer Lue
8 papers · 3 as a fellow
Enrica Marchi
7 papers
LF
Lorenzo Falchi
6 papers · 6 as a fellow
Francesca Montanari
5 papers
Susan Bates
5 papers
MK
Matko Kalac
4 papers · 3 as a fellow
DC
Donald Colbourn
3 papers
Govind Bhagat
3 papers
HM
Helen Ma
3 papers · 3 as a fellow

Clinical trials

Evaluate the Safety of UF-KURE19 Cells in Non-Hodgkin Lymphomas
Principal investigator · Active not recruiting · Phase 1
David Wald
2023–2026
Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma
Principal investigator · Withdrawn · Phase 1
Columbia University
2020–2023
TGR1202 in Relapsed and Refractory Follicular Lymphoma
Principal investigator · Terminated · Phase 2
Columbia University
2017–2020
Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma
Principal investigator · Terminated · Phase 1, Phase 2
Columbia University
2016–2020